INTRODUCTION
Cutaneous T-cell lymphomas are a family of extranodal lymphomas of mature T cells presenting in the skin. Mycosis fungoides (MF) is the most common form, and Sézary syndrome (SS) is a less frequent erythrodermic variant with leukemic involvement. The revised staging system from 2007 1 classifies disease presentation in skin (T), lymph nodes (N), viscera (M), and blood (B). This TNMB classification stratifies patients into those with early-stage (stage IA to IIA) or advanced stage (stage IIB to IVB) disease (Appendix Table A1 , online only). Early stage carries a good prognosis, with survival often exceeding 10 years. [1] [2] [3] A third of patients present with advanced skin disease (T3-4), with median survival times of 35 to 56 months, or nodal disease (median survival, 13 to 25 months). Involvement of viscera is rare. Survival according to stage has been reported from centers, with 5-year overall survival (OS) rates of 40% to 65% for stage IIB, 40% to 57% for stage III, 15% to 40% for stage IVA, and 0% to 15% for stage IVB, whereas at 10 years, up to 40% of stage IIB and III patients were alive. 4 In addition to stage, other potential prognostic markers have been identified in MF/SS. These include clinical features such as male sex and older age, elevated lactate dehydrogenase (LDH), and histologic features of folliculotropism (FT) and large-cell transformation (LCT). [5] [6] [7] [8] [9] [10] [11] Previous studies of prognostic factors have been mainly single-center studies, and only a large-scale international collaboration will allow the true impact of these factors to be defined.
A recent study that proposed a prognostic model of MF/SS based on a large data set (N ϭ 1,502) from a single center in the United Kingdom with a validation set from a single center from the United States 12 prompted the establishment of the Cutaneous Lymphoma International Consortium (CLIC) consortium. CLIC includes board members from established cutaneous lymphoma groups, such as the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Taskforce, International Society for Cutaneous Lymphomas, US Cutaneous Lymphoma Consortium, and United Kingdom Cutaneous Lymphoma Group, and aims to improve understanding of the clinical and translational aspects of these rare lymphomas through collaborative research, using uniform terminology and well-defined end points. We report the results of the initial CLIC 1 retrospective study designed to test the relevance of candidate prognostic markers on OS in advanced-stage MF/SS. The aim was to accurately identify patients with a worse outcome who may not be recognized in the current staging system with the intention of developing a prognostic index.
PATIENTS AND METHODS

Patient Selection and Staging
Specialist cutaneous T-cell lymphoma centers were contacted through membershipofthemajorcutaneouslymphomaorganizations(EuropeanOrganisation for Research and Treatment of Cancer, International Society for Cutaneous Lymphomas, US Cutaneous Lymphoma Consortium, United Kingdom Cutaneous Lymphoma Group). This study was approved by a "mother center" institutional review board at Stanford University and also received local approval. Data were collected retrospectively on consecutive patients from patient records and existing databases. Eligible patients were those diagnosed with clinical stage IIB or higher disease from 2007. 1 Data were collated from centers and reviewed independentlyfordataaccuracyandcompletenessatUniversityHospitalBirminghamand Stanford University. Missing or questionable data were assessed manually, and queries were resolved with centers.
Prognostic Parameters
After a series of CLIC teleconferences from 2012 to 2013 and literature review of prognostic markers in MF/SS, 4 
Statistical Analysis
Percentage of data fields successfully captured at each site and pooled collated data were summarized. Actuarial OS and disease-specific survival for each stage and each prognostic parameter were calculated using the KaplanMeier method. Univariable associations were tested using log-rank tests. Multivariable analyses were performed using the Cox proportional hazards regression model. For multivariable analysis, all variables were included in the model selection process. A backward stepwise approach was taken to select variables with the most predictive power (P Ͻ .10). The proportionality assumption of the final model was tested using Schoenfeld residuals. Missing values were included in the model as an additional category because these may reflect the clinical decision not to perform certain tests. To capture some of the expected variation between centers, a dummy variable for each was included in the model but not reported on in this article. Prognostic markers identified were used in a prognostic model to identify risk groups for advanced MF/SS.
(Appendix Fig A2, online only) . Stage IVA2 includes patients with partial or complete effacement of nodal architecture with atypical lymphocytes (N3). Median survival was 29 months in stage IVA2, with a 5-year survival rate of 32.9%. In comparison, stage IVA1 had a median survival time of 53 months and a 5-year predicted survival rate of 48.3% (P Ͻ .001; Table 3 ). Comparing OS across continents and in patients from the United States versus outside of the United States, there were no significant differences in survival according to stage.
Prognostic Markers
In univariable analyses, stage IV, age greater than 60 years, absent FT, LCT in skin, elevated WBC, and elevated LDH were identified as adverse prognostic factors. Table 2 lists the number of patients, survival ranges, and probability of survival at 1, 2, and 5 years for each parameter.
Age greater than 60 years (n ϭ 813) was associated with a significantly worse OS (P Ͻ .001) and a median survival time of 52 months. Using age Յ 60 years as the reference category, the hazard ratio for survival was 1.35 (95% CI, 1.04 to 1.75) in patients age 60 to 70 years and 1.91 (95% CI, 1.48 to 2.45) in patients age Ն 70 years. Age was also significant as a continuous variable (hazard ratio, 1.03; 95% CI, 1.02 to 1.04; P Ͻ .001), so for every year increase in age, the hazard increased by 3%. The male-to-female ratio was 1.7:1, with no difference in survival according to sex.
FT was present in 17.2% of 1,062 FT-evaluable patients. In univariable analysis, those with absent FT in skin had a significantly worse prognosis than those with FT (P Ͻ .001). LCT in skin was present in 19.6% of 1,098 LCT-evaluable patients at diagnosis (including Ͼ 50% with stage IIB disease). LCT in skin was independently associated with a worse prognosis (P ϭ .003), with an OS of 49.8 months and 5-year survival of 39%. There was no association between LCT and FT. CD30 ϩ and Ki-67 positivity were intended to be recorded as absolute percentages, but a number of centers only recorded a range. Percentages of CD30 ϩ and Ki-67 positivity of more than 10% and more than 20%, respectively, were considered positive, which allowed most data to be included. The cutoff is arbitrary because no percentage number has been agreed upon in MF/SS and varying percentages of positivity are reported.
14 CD30 ϩ was present in 149 patients (23.3%), and Ki-67 positivity was present in 182 patients (38.6%). No difference in survival between patients positive or negative for CD30 or Ki-67 was shown for the cohort, but in T3 disease, both CD30 ϩ and Ki-67 positivity were significantly associated with a worse survival (P Ͻ .001 and P ϭ .04, respectively).
Elevated WBC count was associated with a worse prognosis, with a median survival time of 38 months versus 54 months in patients without an elevated WBC count (P ϭ .006). Elevated ALC did not carry a significantly worse prognosis for the whole cohort or those with T4 disease (P ϭ .358 and P ϭ .4, respectively). Four hundred fifty-seven patients (62%) had a documented blood clone, and this was identical to the skin clone in 357 patients (49%). Patients with an identical blood clone had a worse prognosis, with a median survival of 49.8 months compared with 73.4 months in patients without an identical blood clone (P ϭ .086). Serum LDH was elevated in 457 patients (51.1%). An elevated LDH was an adverse risk factor, with a median survival time of 44.7months compared with 78.8 months in patients with a normal LDH (P Ͻ .001).
Prognostic Index Model
In multivariable analysis, stage IV disease (P ϭ .009), age greater than 60 years (P Ͻ .001), LCT in the skin (P Ͻ .001), and elevated serum LDH (P Ͻ .001) were all independent prognostic variables for worse survival. Using these four variables, we built a prognostic index model in the subset of patients with a complete data set (N ϭ 857; IIB, n ϭ 277; III, n ϭ 220; IV, n ϭ 360), where zero or one variable equals low risk, two variables equal intermediate risk, and three to four variables equal high risk. This model distinguishes risk groups across stage, with 5-year predicted OS rates of 67.8% (low risk), 43.5% (intermediate risk), and 27.6% (high risk; P Ͻ .001, Table 4 , and Fig 2) .
DISCUSSION
To our knowledge, this study represents the largest reported cohort of patients with advanced-stage MF/SS (n ϭ 1,275). It involves an unprecedented scale of international collaboration including patients from 29 centers spanning five continents. The results confirm poor survival in patients with advanced MF/SS, with a median OS of 63 months, 2-year survival of 77%, and 5-year survival of 52%. Using stage IIB as the comparator (median OS, 68 months), we were unable to fully validate the revised staging; survival in stage IIIA was in fact slightly improved; the trend in stage IIIB and IVA1 was worse but did not reach statistical significance, whereas OS for stage IV disease was significantly worse (48 months for stage IVA and 33 months for stage IVB).
In univariable analyses, six of 10 variables tested were significantly associated with a worse survival. These included stage IV, age greater than 60 years, absent FT in skin, LCT in skin, elevated WBC, and elevated LDH (Table 2 ). An identical clone in skin and blood was associated with a trend toward a worse survival (P ϭ .086).
Older age has previously been suggested to be associated with a worse survival in advanced MF/SS. 7, 9, 10 The mean age of this cohort was 63 years and was similar across stages. Both age greater than 60 years and greater than 70 years were independent adverse prognostic markers. Older patients may have compromised OS as a result of multiple factors including comorbidities and more limited treatment This cohort showed a male predominance, with a male-tofemale ratio of 1.7:1, which is similar to previous reports, 3, 5, 7 but no difference in survival was shown between sexes. Male sex has been associated with a worse prognosis in some studies 7 but is not a consistent finding. 3, 5, 9, 15 Histologic features of FT, LCT, CD30 positivity, and a high proliferation index may be associated with aggressive disease. FT is reported when atypical lymphocytes are invading the follicular epithelium. Absent FT may result if the biopsy does not contain a follicle. Data completeness for FT and LCT was robust (Ͼ 80%), which reflects the ability to record these features on hematoxylin and eosin-stained slides. FT has been associated with treatment resistance and worse survival often in the context of early-stage disease. Among patients with stage IB disease who have FT, survival outcome is similar to patients with stage IIB disease, and FT may confer a worse prognosis in patients with LCT. 5, 7, [16] [17] [18] [19] Conversely, in this advanced data set, the presence of FT was associated with a better prognosis in univariable analysis. However, FT was strongly associated with stage IIB disease and a younger age (median age, 59 years v 65 years without FT), and both confer a better prognosis. Moreover, FT was not significant in multivariable analysis. Other possibilities include that FT is a marker for progression from stage IB disease to advanced disease or that therapies in early-stage disease fail to treat FT disease, allowing progression, whereas patients with advanced disease with FT have systemic therapies capable of treating deep follicular disease. Alternatively, in early disease, the lack of highly relevant poor prognostic variables found in advanced disease such as elevated LDH and LCT makes FT significant. Benton et al 12 similarly found FT to be a strong predictor of poor survival in early-stage but not late-stage patients. Another explanation is that because FT is a skin-only marker, when one takes into account extracutaneous disease, adverse outcome of stage IV trumps any risk factor in skin. Further prospective studies of FT may determine whether this feature is relevant to survival or treatment response or is a predictor of progression in those with early-stage disease.
LCT in skin was an independent poor prognostic marker in this cohort, confirming earlier studies, 5, 8, 9, 20 and remained significant in patients with skin tumors and erythroderma. The definition of LCT of more than 25% of atypical lymphocytes or clusters of cells having a diameter of more than four times that of normal lymphocytes has been widely accepted. 13 This definition allows comparisons between sites, and LCT is likely of prognostic importance. Further studies of LCT occurring at the time of disease progression and in extracutaneous sites such as lymph nodes will be informative.
CD30 and Ki-67 require special stains, and data completeness was 50% and 37%, respectively. Incomplete data (both not recorded and not done) may add bias because more thorough investigations may be associated with aggressive disease. Furthermore, the protocol stipulated that CD30 and Ki-67 should be recorded as absolute percentages (0% to 100%), but many centers had only recorded ranges. Unlike LCT, CD30 positivity has no standard definition, and variable reporting may account for conflicting reports in the literature. 5, 9, 21 We scored CD30 as positive if more than 10% of tumoral cells stained positively. Although we found a worse OS in CD30 ϩ patients, this was not statistically significant for the whole cohort but was associated with a worse OS in those with skin tumors (T3; P Ͻ .001). Ki-67 protein reflects tumor cell proliferation, and a higher growth fraction is associated with a worse prognosis in multiple cancers. In our data set, we used a threshold value of 20% Ki-67-positive cells. No significance in OS was demonstrated for those with a low or high Ki-67 in the cohort as a whole, but as with CD30 ϩ , high Ki-67 was associated with a significantly worse OS in those with skin tumors (T3; P ϭ .04). Standardized histologic assessment will be required to determine whether any of these pathologic features are relevant prognostically.
Blood involvement characterizes SS but may also be seen at lower levels in classical MF. We found a trend toward a worse survival with increasing blood involvement, as reflected in OS times in stage IIIA, IIIB, and IVA1 disease (Appendix Fig A1) . Similarly, total ALC is, at times, used to track peripheral-blood tumor burden. Both elevated and low ALCs seemed to carry a worse survival than ALC in the normal range, but neither reached statistical significance. ALCs greater than 10 ϫ 10 9 /L may have a poorer prognosis. 22, 23 This study confirmed that patients with counts greater than 10 ϫ 10 9 /L had a worse prognosis, but this did not reach statistical significance (P ϭ .066). Elevated WBC, which partially reflects ALC, was significantly associated with a worse prognosis compared with normal (or low) WBC in univariable but not multivariable analysis. Other factors that affect WBC, such as the eosinophil count, have been associated with a worse prognosis in SS 24 and may be relevant to study in future trials.
The presence of an identical clone in skin and blood clone is classified as a (no clone) or b (clone) alongside blood (B) classification. The presence of a blood clone does not currently alter stage but provides a means of recording low-level blood involvement. An identical blood clone was detected in 49% of patients in this advanced cohort and was associated with a trend toward a worse survival, with median survival time of 49.8 months (P ϭ .086). An identical blood clone has been associated with a worse outcome in early-stage MF but may not be relevant in advanced disease where tumor burden is already greater.
Forty-nine percent of this cohort had elevated LDH, which was an independent poor prognostic marker for OS (P ϭ .002). Elevated LDH is associated with a worse survival in a number of lymphomas and is used in prognostic indices for aggressive follicular and mantlecell lymphomas.
25-27
Prognostic indices may be developed to stratify patients according to survival by combining prognostic factors. A prognostic index must be simple and reproducible. Prognostic indices are useful when there is a wide range of survival between stages and a variety of prognostic variables. MF/SS fits this characterization. Furthermore treatment in MF/SS is frequently decided on an individual patient basis with consideration of prognostic factors beyond stage. Four variables (stage IV, age Ͼ 60 years, elevated LDH, and LCT in skin) were independently prognostic for survival in this study. Using these four variables in a prognostic index model, we identified the following three risk groups with significantly different survival: low risk (zero to one variable), intermediate risk (two variables), and high risk (three to four variables), with 5-year predicted OS rates of 67.8%, 43.5%, and 27.6%, respectively ( Table 4, Fig 2) . Benton et al 12 recently reported separate cutaneous lymphoma prognostic indices for early-stage (IA to IIA) and advanced-stage (IIB to IVB) MF/SS. The advanced-stage index was developed using retrospective data but included a much smaller number of advanced-stage patients (derivation set, n ϭ 445). Age greater than 60 years was also identified as a significant adverse prognostic factor in the late-stage model. Male sex carried a poorer survival but was not found to be important in our data set (P ϭ .93). The other factors included in this index were related to stage (N2/3, B1/2, and M1). A lack of full data on LDH precluded inclusion.
This study of advanced stages of MF/SS confirms stage IV as a poor prognostic stage and identifies increasing age, elevated LDH, and LCT in the skin as independent poor prognostic markers that may be used together in a prognostic model to identify three risk groups across stages with significantly different survival ( Table 4, Fig 2) . This retrospective study has proven the ability of these international centers to work together, but the accuracy or consistency of data entry relating to the interpretation of pathology reports cannot be confirmed because no quality assessment of data entry was performed. A prospective study with consensus criteria, consistently collected data, central pathologic review, and data monitoring is planned by CLIC to test these parameters with others and further refine and validate this prognostic index in advanced MF/SS. 
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